Stool DNA and colorectal-cancer screening

New England Journal of Medicine

Volumn 370, Issue 14, 2014, Pages 1350-1351

  Robertson, Douglas J ^a,b   Dominitz, Jason A ^c  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HEMOGLOBIN;

CANCER GROWTH; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; DNA SCREENING; EDITORIAL; EPIGENETICS; FECES ANALYSIS; GENETIC ALGORITHM; HEALTH SERVICE; HUMAN; NON PROFIT ORGANIZATION; OCCULT BLOOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY;

COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EARLY DETECTION OF CANCER; FECES; FEMALE; HUMANS; MALE; MASS SCREENING; PRECANCEROUS CONDITIONS;

EID: 84897522927     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1400092     Document Type: Editorial

References (14)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-73.
3. Vital signs: colorectal cancer screening test use - United States, 2012. MMWR Morb Mortal Wkly Rep 2013;62:881-8.
4. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:627-37.
5. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
6. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14. (Pubitemid 39665324)
7. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287-97.
8. van Roon AH, Goede SL, van Ballegooijen M, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 2013;62:409-15.
9. Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 2012;10:633-8.
10. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004;126:1270-9. (Pubitemid 38552791)
11. Deenadayalu VP, Rex DK. Fecal-based DNA assays: a new, noninvasive approach to colorectal cancer screening. Cleve Clin J Med 2004;71:497-503. (Pubitemid 38832613)
12. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366:697-706.
13. Schroy PC III, Heeren TC. Patient perceptions of stool-based DNA testing for colorectal cancer screening. Am J Prev Med 2005;28:208-14. (Pubitemid 40254272)
14. Draft research plan: screening for colorectal cancer. Rockville, MD: U.S. Preventive Services Task Force, 2014 (http://www.uspreventiveservicestaskforce. org/uspstf14/coloncan/coloncandraftresplan.htm).